Fedme
Studie anbefaler behandling for alle barn med fedme
Rapportert av AI Bilde generert av AI
En ny studie fra Karolinska Institutet viser at barn med moderat fedme har høyere risiko for å utvikle type 2-diabetes, høyt blodtrykk og lipidforstyrrelser i voksen alder, selv uten synlige risikomarkører. Forskerne anbefaler behandling for alle disse barna.
Study identifies how SLIT3 helps brown fat build blood vessels and nerves needed for calorie burning
Researchers report that a protein signal called SLIT3 helps brown fat ramp up heat production by coordinating the growth of blood vessels and sympathetic nerves. In experiments using mouse models and human cells and tissue datasets, the team found SLIT3 is cut into two fragments with distinct roles—one linked to vessel growth and the other to nerve expansion—pointing to possible future obesity-treatment strategies aimed at boosting energy expenditure.
Rapportert av AI
A real-world study of nearly 8,000 patients by Cleveland Clinic researchers shows that stopping injectable semaglutide or tirzepatide often does not lead to major weight regain. Many participants maintained or continued losing weight by restarting treatment, switching medications, or using lifestyle support. This differs from clinical trials where rapid regain was observed.
A new American Heart Association scientific statement published Feb. 25, 2026 in Circulation projects that cardiovascular risk factors such as high blood pressure, obesity and diabetes will become more common among U.S. women by 2050, with particularly steep increases forecast for some younger women and for several racial and ethnic groups.
Rapportert av AI
A new Cochrane review of 22 clinical trials shows that intermittent fasting does not lead to greater weight loss than standard diet advice for overweight or obese adults. The analysis, involving nearly 2,000 participants, challenges the popularity of fasting methods amid rising global obesity rates. Researchers emphasize the need for more long-term studies and personalized approaches.
Brazil's Anvisa approved on Monday, February 2, 2026, the expansion of therapeutic indications for semaglutide, the active ingredient in Wegovy and Ozempic. Wegovy can now be used to reduce the risk of heart attacks and strokes in adults with cardiovascular disease and overweight, while Ozempic is indicated for type 2 diabetes associated with chronic kidney disease. The agency is also reviewing a request for an oral version of Wegovy.
Rapportert av AI Faktasjekket
Where fat is stored in the body—not only how much—is linked to brain structure and cognition, according to a large MRI study of nearly 26,000 UK Biobank participants. Researchers reported that two fat distribution profiles—one marked by high pancreatic fat and another often described as “skinny fat,” with high fat relative to muscle despite a less-obese appearance—were associated with gray-matter loss, faster brain aging and poorer cognitive outcomes.
Six-month ‘Sweet Tooth Trial’ finds changing sweet-tasting foods does not shift sweetness liking or key metabolic markers
torsdag, 19. mars 2026, 14:37Study finds prediabetes remission possible without weight loss
torsdag, 19. mars 2026, 03:05Belly fat linked to heart failure risk even in normal-weight people
tirsdag, 17. mars 2026, 11:3194% of Hong Kong students lack exercise, 17.5% overweight, study shows
søndag, 15. mars 2026, 09:38Study finds 1990s Indonesian rice price surge stunted children
fredag, 13. februar 2026, 21:37Debate on banning ultra-processed foods in school canteens divides opinions
onsdag, 11. februar 2026, 10:54Cochrane reviews assess GLP-1 drugs for obesity treatment
tirsdag, 10. februar 2026, 00:38Obesity triples risk of severe infections
søndag, 8. februar 2026, 13:54Gut compound indole protects offspring from fatty liver disease
torsdag, 5. februar 2026, 11:02Senator Raffy Tulfo refiles bill for health ratings on food packages